ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer

Liang, Xiaomei; Yang, Yulu; Huang, Chuanqing; Ye, Zhibin; Lai, Wujiang; Luo, Jiamao; Li, Xiaoxuan; Yi, Xiao; Fan, Jun-Bing*; Wang, Ying; Wang, Yifeng*南方医科大学; y
Journal of Controlled Release2023-4DOI: 10.1016/j.jconrel.2023.03.017
4被引11阅读
引用收藏
分享

摘要

Resistance to the chemotherapeutic agent cisplatin (DDP) is the primary reason for invalid chemotherapy of ovarian cancer. Given the complex mechanisms underlying chemo-resistance, the design of combination therapies based on blocking multiple mechanisms is a rationale to synergistically elevate therapeutic effect for effectively overcoming cancer chemo-resistance. Herein, we demonstrated a multifunctional nanoparticle (DDPOla@HR), which could simultaneously co-deliver DDP and Olaparib (Ola, DNA damage repair inhibitor) using targeted ligand cRGD peptide modified with heparin (HR) as nanocarrier, enabling the concurrent tackling of multiple resistance mechanisms to effectively inhibit the growth and metastasis of DDP-resistant ovarian cancer. In combination strategy, heparin could suppress the function of multidrug resistance-associated protein 2 (MRP2) and P-glycoprotein (P-gp) to promote the intracellular accumulation of DDP and Ola by specifically binding with heparanase (HPSE) to down-regulate PI3K/AKT/mTOR signaling pathway, and simultaneously served as a carrier combined with Ola to synergistically enhance the anti-proliferation ability of DDP for resistant ovarian cancer, thus achieving great therapeutic efficacy. Our DDP-Ola@HR could provide a simple and multifunctional combination strategy to trigger an anticipated cascading effect, thus effectively overcoming the chemo-resistance of ovarian cancer.

学科与关键词

关键词
Heparin-based nanoparticlesMultiple chemo-resistance mechanismsOlaparibCisplatinABC -transporterDNA damage repair
相关
加载中…
  • Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP
    Liu, Yuan; Wang, Yiru; Guan, Xue; Wu, Qiong; Zhang, Mengjun; Cui, Ping; Wang, Can; Chen, Xiuwei*; Meng, Xianwei*; Ma, Tengchuang*ACS applied materials & interfaces, 2023, 15(22): 26484-26495.被引 1
  • Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer
    Wang, Yupeng; Luo, Zhijian; Zhou, Dongfang; Wang, Xuefeng; Chen, Jianjun; Gong, Shipeng; Yu, Zhiqiang*Biomaterials Science, 2021, 9(11): 4110-4119.被引 19
  • Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway
    Luo, Zhijian; Luo, Yantao; Liang, Xiaoling; Lyu, Qingyang; Meng, Fanliang; Chen, Xuncai; Wang, Yupeng; Fang, Weiyi*; Li, Aimin*; Zhou, Dongfang*ACS Biomaterials Science & Engineering, 2022, 8(6): 2526-2536.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Controlled Release
发表日期
2023-04
卷期
第 356 卷
页码
691-701
DOI
10.1016/j.jconrel.2023.03.017
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773291, 22075127, 22275080]; Guangdong Basic and Applied Basic Research Foundation [2021A1515011638, 2022A1515012044]

作者

  • L

    Liang, Xiaomei (第一作者)

  • Y

    Yang, Yulu

查看全部 11 位作者收起作者
  • H

    Huang, Chuanqing

  • Y

    Ye, Zhibin

  • L

    Lai, Wujiang

  • L

    Luo, Jiamao

  • L

    Li, Xiaoxuan

  • Y

    Yi, Xiao

  • F

    Fan, Jun-Bing (通讯)

    southern med univ

  • W

    Wang, Ying

  • W

    Wang, Yifeng (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417